{"id":63589,"title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.","abstract":"","date":"2014-03-21","categories":"Hemic and Lymphatic Diseases","split":"train","url":"http://www.ncbi.nlm.nih.gov/pubmed/24421329","annotations":[{"name":"Clinical trial","weight":0.786982,"wikipedia_article":"http://en.wikipedia.org/wiki/Clinical_trial"},{"name":"Dexamethasone","weight":0.0311921,"wikipedia_article":"http://en.wikipedia.org/wiki/Dexamethasone"},{"name":"Multiple myeloma","weight":0.0297972,"wikipedia_article":"http://en.wikipedia.org/wiki/Multiple_myeloma"},{"name":"Drug metabolism","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Drug_metabolism"},{"name":"Phase (matter)","weight":0.0147415,"wikipedia_article":"http://en.wikipedia.org/wiki/Phase_(matter)"},{"name":"Refractory","weight":0.0137481,"wikipedia_article":"http://en.wikipedia.org/wiki/Refractory"}]}
